Halozyme Therapeutics, Inc.
HALO
$107.39
-$0.92-0.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 53.23% | 205.97% | -180.81% | 6.09% | 39.85% |
| Total Depreciation and Amortization | 0.69% | 26.44% | 30.66% | -0.40% | 0.26% |
| Total Amortization of Deferred Charges | 0.40% | 15.13% | 4.95% | 0.32% | 0.33% |
| Total Other Non-Cash Items | -9.52% | -94.07% | 767.12% | 833.92% | -33.70% |
| Change in Net Operating Assets | -66.29% | -177.84% | 83.82% | 36.67% | -1,331.52% |
| Cash from Operations | 33.77% | -17.78% | 22.64% | 79.11% | -35.35% |
| Capital Expenditure | -11.55% | -162.16% | 52.90% | -93.86% | -64.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -100.00% | 100.10% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -38,080.52% | 101.07% | -107.03% | 136.99% | 196.51% |
| Cash from Investing | -2,078.07% | 99.61% | -467.93% | 137.78% | 193.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -74.84% | 1,271.13% | -- |
| Repurchase of Common Stock | -20,427.96% | -- | 100.00% | 87.05% | -8,938.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20,126.35% | -100.67% | 1,169.17% | 92.51% | -8,902.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.30% | 161.99% | -179.16% | 412.58% | -289.27% |